Statkraft has secured a PPA with biopharmaceutical company AstraZeneca to offtake the energy from three wind farms in Sweden.
The agreement is based on the commissioning of the new wind farms in Strömstad and Årjäng, which is in Sweden’s bidding area 3 (SE3), where AstraZeneca’s research and manufacturing facilities are also situated.
The wind farms are owned by Rabbalshede Kraft, who will also be responsible for their operation.
Under the agreement, AstraZeneca commits to purchasing 200GWh per year for ten years, equivalent to two terawatt-hours.
This corresponds to approximately 80% of the company’s total electricity needs at its research facility in Gothenburg and manufacturing facility in Södertälje.AstraZeneca in Sweden has been using 100% certified renewable energy for several years.
Through the agreement with Statkraft, the company will also be able to increase access to renewable energy in the community where it operates.
President of AstraZeneca for Sweden Per Alfredsson said: “We want to contribute to the green transition in society.
“It is important for us to support initiatives that increase the availability of renewable energy.
“To successfully mitigate climate change, we must collaborate across different sectors and think beyond our own operations. Here we see an opportunity to contribute to the increase of renewable energy in society.” Hallvard Granheim, executive vice president markets at Statkraft, added: “We are very pleased to support this ambitious initiative for a sustainable transition.
“This agreement confirms the role of Statkraft as a leading supplier of renewable energy to Nordic industries and our ambition to be a leading market integrator in the energy system.”